{"organizations": [], "uuid": "01686cf5a06bb0b93e75af6f4fcbc4baf8c43380", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/9", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/27/business-wire-ocular-therapeutixa-to-report-fourth-quarter-2017-financial-results.html", "country": "US", "domain_rank": 767, "title": "Ocular Therapeutix™ To Report Fourth Quarter 2017 Financial Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.016, "site_type": "news", "published": "2018-02-28T00:00:00.000+02:00", "replies_count": 0, "uuid": "01686cf5a06bb0b93e75af6f4fcbc4baf8c43380"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/27/business-wire-ocular-therapeutixa-to-report-fourth-quarter-2017-financial-results.html", "ord_in_thread": 0, "title": "Ocular Therapeutix™ To Report Fourth Quarter 2017 Financial Results", "locations": [], "entities": {"persons": [], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "bedford", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "ocular therapeutix", "sentiment": "none"}, {"name": "company", "sentiment": "none"}, {"name": "eastern time", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report ended December 31, 2017 financial results on Thursday, March 8, 2018. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the Company’s financial results and provide a general business update.\nThe live webcast can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com . Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (844) 464-3934 (U.S.) or (765) 507-2620 (International) to listen to the live conference call. The conference ID number for the live call will be 9371369. An archive of the webcast will be available until March 15, 2018 on the Company’s website.\nAbout Ocular Therapeutix, Inc.\nOcular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. Ocular Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. The Company’s earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180227006558/en/\nInvestors\nOcular Therapeutix\nDonald Notman\nChief Financial Officer\ndnotman@ocutx.com\nor\nWestwicke Partners\nChris Brinzey\nManaging Director\nchris.brinzey@westwicke.com\nor\nMedia\nOcular Therapeutix\nScott Corning\nVice President of Marketing & Commercial Operations\nscorning@ocutx.com\nSource: Ocular Therapeutix, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Finvestors.ocutx.com%2Fphoenix.zhtml%3Fc%3D253650%26p%3Dirol-irhome&esheet=51765540&newsitemid=20180227006558&lan=en-US&anchor=investors.ocutx.com&index=1&md5=f4fce28b3acd90a9d9de7c7c3e64e527", "http://www.businesswire.com/news/home/20180227006558/en/"], "published": "2018-02-28T00:00:00.000+02:00", "crawled": "2018-02-28T02:16:32.026+02:00", "highlightTitle": ""}